Phase I Study of Pemetrexed, Cisplatin, and Concurrent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer (Q53226152)

12 May 2018

title

Phase I Study of Pemetrexed, Cisplatin, and Concurrent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer (English)

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

1 December 2024

author name string

Bao-Sheng Li

1

1 reference

12 May 2018

He-Yi Gong

2

1 reference

12 May 2018

Wei Huang

3

1 reference

12 May 2018

Yan Yi

4

1 reference

12 May 2018

Jin-Mimg Yu

5

1 reference

12 May 2018

Zhong-Tang Wang

6

1 reference

12 May 2018

Zi-Cheng Zhang

7

1 reference

12 May 2018

Hong-Fu Sun

8

1 reference

12 May 2018

Hong-Sheng Li

9

1 reference

12 May 2018

Li-Ying Wang

10

1 reference

12 May 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21555933

1 December 2024

publication date

1 April 2012

1 reference

12 May 2018

April 2012

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21555933

full work available at URL

1 December 2024

http://journals.lww.com/00000421-201204000-00004

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

American Journal of Clinical Oncology

1 December 2024

published in

1 reference

12 May 2018

volume

35

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

115-119

1 reference

12 May 2018

Cancer burden in the year 2000. The global picture

cites work

1

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Multidisciplinary management of lung cancer

1 December 2024

3

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 December 2024

4

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience

1 December 2024

5

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis

1 December 2024

6

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 December 2024

7

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis

1 December 2024

8

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer

1 December 2024

9

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 S

1 December 2024

10

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer

1 December 2024

12

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.

1 December 2024

13

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

1 December 2024

14

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 December 2024

16

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 December 2024

17

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

1 December 2024

18

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 December 2024

19

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 December 2024

20

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 December 2024

21

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 December 2024

22

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro

1 December 2024

23

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer

1 December 2024

24

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer

1 December 2024

26

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

1 December 2024

27

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

1 December 2024

28

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer.

1 December 2024

29

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 December 2024

30

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

1 December 2024

32

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer

1 December 2024

33

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study

1 December 2024

34

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage I

1 December 2024

35

1 reference

https://api.crossref.org/works/10.1097/COC.0B013E318209AB93

1 December 2024

Identifiers

1 reference

12 May 2018

1 reference

12 May 2018